Cullinan Therapeutics, Inc. — Form 8-K Summary
Report date: June 1, 2024; filed June 3, 2024. This Form 8-K reports Regulation FD disclosures and other events regarding initial clinical data for zipalertinib. It is not a quarterly or annual financial report, and the filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.
Business Context and Reporting Period
Cullinan is co-developing zipalertinib with an affiliate of Taiho Pharmaceutical for patients with non-small cell lung cancer containing EGFR exon 20 insertion mutations. The disclosure concerns the pivotal Phase 2b portion of the REZILIENT1 trial, specifically patients previously treated with amivantamab.
Clinical results were based on a January 12, 2024 data cutoff. Thirty-one patients had been enrolled, and 18 were evaluable for response.
Clinical and Other Key Metrics
| Measure | REZILIENT1 Module C | Prior Phase 1/2a post-chemotherapy results |
|---|---|---|
| Population | Post-chemotherapy and amivantamab, with or without other exon 20 insertion treatment; N=18 | Post-chemotherapy; N=39 |
| Confirmed overall response rate | 39% | 41% |
| Disease control rate | 94% | 97% |
| Duration of response | Not yet estimable | Not yet estimable |
| Progression-free survival | Not yet estimable | 12 months |
Patients had received a median of three prior systemic anti-cancer regimens, including platinum-based chemotherapy, anti-PD1/L1 therapy, and EGFR tyrosine kinase inhibitor therapy. Zipalertinib’s safety profile was described as manageable and similar to prior reports; no Grade 4 or Grade 5 treatment-related adverse events were reported in the disclosed dataset.
Material Changes, Outlook, and Risks
- The company reported initial evidence of anti-tumor activity in patients treated after amivantamab, described as similar to activity previously observed after chemotherapy alone.
- Both Module B2, for patients treated after chemotherapy only, and Module C, for patients treated after approved exon 20 insertion mutation therapies, remained on track to complete enrollment by year-end 2024.
- Additional REZILIENT trials are ongoing in first-line and second-line exon 20 insertion NSCLC and in populations including patients with active brain metastases and uncommon EGFR mutations.
- The results are interim clinical data from a small response-evaluable population. Duration of response and progression-free survival for Module C were not yet estimable, and the filing does not provide statistical significance, comparative control data, or final trial results.
- Future development remains subject to enrollment, clinical efficacy and safety outcomes, regulatory review, and other risks typical of drug development.
Investor Verification Checklist
- Verify the full June 1, 2024 press release and investor presentation furnished as Exhibits 99.1 and 99.2.
- Confirm the January 12, 2024 data cutoff, 31 enrolled patients, and 18 response-evaluable patients.
- Assess whether subsequent data establish mature duration of response, progression-free survival, and overall survival outcomes.
- Monitor completion of enrollment for Modules B2 and C by year-end 2024 and any resulting regulatory plans.
- Review the complete safety dataset, including adverse events not characterized in this filing.
- Review later SEC filings for financial position, cash runway, development spending, collaboration economics, and potential financing needs; these items are not provided here.